Emerging Therapeutics in the U.S. Colorectal Cancer Markets

Table of Contents

• 1. U.S. Total Market for Colorectal Cancer
  • 1. Executive Summary
    • 1. Executive Summary
  • 2. Research Scope and Methodology
    • 1. Scope and Segmentation
    • 2. Research Methodology
  • 3. Disease Overview
    • 1. Introduction
    • 2. Etiology
    • 3. Screening
    • 4. Diagnosis and Staging
    • 5. Treatment Overview
  • 4. Patient Forecasts
    • 1. Incidence and Staging Forecasts
    • 2. Patient Forecasts by Line of Therapy
    • 3. Unmet Need Population Forecasts
  • 5. Total Market Forecasts
    • 1. Total Market Forecasts
    • 2. Market Share Analysis
    • 3. Adjuvant Therapy Forecasts
    • 4. First-line Therapy Forecasts
    • 5. Second and Third-line Therapy Forecasts
  • 6. General Market Trends
    • 1. Industry Challenges
    • 2. Market Drivers
    • 3. Market Restraints
  • 7. Frost & Sullivan Awards
    • 1. Company of the Year Award
    • 2. Product of the Year Award
    • 3. Entrepreneurial Company of the Year Award
    • 4. Product Differentiation Innovation of the Year Award
    • 5. Best Bang for the Buck Award
• 2. U.S. Cytotoxic Therapies Market for Colorectal Cancer
  • 1. Overview
    • 1. Introduction
    • 2. Market Engineering Measurements
  • 2. Forecasts and Trends
    • 1. Dosage and Cost of Therapy Estimations
    • 2. 5-FU Forecasts
    • 3. Camptosar/Generic Forecasts
    • 4. Eloxatin/Generic Forecasts
    • 5. Xeloda Forecasts
    • 6. Edotecarin Forecasts
  • 3. Competitive Analysis
    • 1. Competitive Structure
    • 2. Market Share Analysis
    • 3. Product Analysis
    • 4. Pipeline Analysis
• 3. U.S. Targeted Therapies Market for Colorectal Cancer
  • 1. Overview
    • 1. Introduction
    • 2. Market Engineering Measurements
  • 2. Angiogenesis Pathway
    • 1. Mechanism of Action
    • 2. Product Analysis
    • 3. Pipeline Analysis
  • 3. EGF Pathway
    • 1. Mechanism of Action
    • 2. Product Analysis
    • 3. Pipeline Analysis
  • 4. Cell Proliferation/Apoptosis Pathway
    • 1. Mechanism of Action
    • 2. Pipeline Analysis
  • 5. Immune Response Pathway
    • 1. Mechanism of Action
    • 2. Pipeline Analysis
  • 6. Revenue Forecasts
    • 1. Dosage and Cost of Therapy Estimations
    • 2. Avastin Forecasts
    • 3. Erbitux Forecasts
    • 4. PTK787 Forecasts
    • 5. ABX-EGF Forecasts
  • 7. Competitive Analysis
    • 1. Competitive Structure
    • 2. Market Share Analysis
• 4. Appendix
  • 1. Decision Support Databases
    • 1. Physicians
    • 2. Total Male Population
    • 3. Total Female Population
    • 4. Mortality of Colorectal Cancer
    • 5. Red Meat Consumption

List Of Figures

U.S. Total Market

• Colorectal Cancer Market: Most Common Chemotherapy Regimens (U.S.), 2004
• Colorectal Cancer Market: Patient Forecasts of Colon Cancer Incidence by Stages (U.S.), 2001-2011
• Colorectal Cancer Market: Patient Forecasts of Rectal Cancer Incidence by Stages (U.S.), 2001-2011
• Adjuvant Therapy Colorectal Cancer Market: Patient Forecasts (U.S.), 2001-2011
• First-line Therapy Colorectal Cancer Market: Patient Forecasts (U.S.), 2001-2011
• Second- and Third-line Therapy Colorectal Cancer Market: Patient Forecasts (U.S.), 2001-2011
• Colorectal Cancer Market: Untreated Stage IV Patient Forecasts (U.S.), 2001-2011
• Colorectal Cancer Market: Unmet Need Patient Forecasts (U.S.), 2001-2011
• Colorectal Cancer Market: Revenue Forecasts (U.S.), 2001-2011
• Colorectal Cancer Market: Company Market Share by Revenues (U.S.), 2004
• Colorectal Cancer Market: Company Market Share by Treatment Months (U.S.), 2004
• Colorectal Cancer Market: Adjuvant Therapy Revenue Forecasts (U.S.), 2004-2011
• Colorectal Cancer Market: First-line Therapy Revenue Forecasts (U.S.), 2004-2011
• Colorectal Cancer Market: Second- and Third-line Therapy Revenue Forecasts (U.S.), 2004-2011
• Colorectal Cancer Market: Impact of Top Industry Challenges (U.S.), 2005-2011
• Colorectal Cancer Market: Market Drivers Ranked in Order of Impact (U.S.), 2005-2011
• Colorectal Cancer Market: Market Restraints Ranked in Order of Impact (U.S.), 2005-2011

U.S. Cytotoxic Therapies

• Cytotoxic Therapy Colorectal Cancer Market: Revenue Forecasts (U.S.), 2001-2011
• Cytotoxic Therapy Colorectal Cancer Market: Dosage and Cost of Therapy Estimations (U.S.), 2004
• Cytotoxic Therapy Colorectal Cancer Market: Revenue Forecasts for 5-FU (U.S.), 2001-2011
• Cytotoxic Therapy Colorectal Cancer Market: Revenue Forecasts for Camptosar/Generics (U.S.), 2001-2011
• Cytotoxic Therapy Colorectal Cancer Market: Revenue Forecasts for Eloxatin/Generics (U.S.), 2001-2011
• Cytotoxic Therapy Colorectal Cancer Market: Revenue Forecasts for Xeloda (U.S.), 2001-2011

U.S. Targeted Therapies

• Targeted Therapy Colorectal Cancer Market: Angiogenesis Pipeline Overview (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: EGF Pipeline Overview (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: Cell Proliferation/Apoptosis Pipeline Overview (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: Immune Response Pipeline Overview (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: Dosage and Cost of Therapy Estimations (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: Revenue Forecasts for Avastin (U.S.), 2001-2011
• Targeted Therapy Colorectal Cancer Market: Revenue Forecasts for Erbitux (U.S.), 2001-2011
• Targeted Therapy Colorectal Cancer Market: Revenue Forecasts for PTK787 (U.S.), 2001-2011
• Targeted Therapy Colorectal Cancer Market: Revenue Forecasts for ABX-EGF (U.S.), 2001-2011
• Targeted Therapy Colorectal Cancer Market: Competitive Structure (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: Market Share Analysis by Revenues (U.S.), 2004
• Targeted Therapy Colorectal Cancer Market: Market Share Analysis by Treatment Months (U.S.), 2004